Research Funding

NCCN Investigator Initiated Clinical Studies in the Treatment of Specific Solid Tumors

Deadline: July 23, 2012

In brief, investigators are asked to submit short proposals detailing proposed studies. The overall aim of this RFP is to develop innovative single agent and combination studies of tivozanib in colorectal cancer, breast cancer, ovarian cancer, hepatoma and prostate cancer. Other tumors of interest may be considered depending on the scientific merit of the concept. It is hoped that the proposals submitted in response to this RFP will prove useful in guiding the further development of tivozanib. Collaborative studies between NCCN members are encouraged.


Leave a Reply

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.